Proposed article structure
Highlights
Clinical background
Study design and methods
Key results
Mechanistic and clinical interpretation
Strengths and limitations
Implications for practice and research
Funding, registration, and citation
Highlights
Tirzepatide was associated with broad, dose-related improvements in several cardiovascular risk biomarker domains over 72 weeks in adults with overweight or obesity from SURMOUNT-1.
The strongest and most consistent effects were seen in markers of inflammation, insulin resistance, adiposity and hepatic stress, endothelial dysfunction, and impaired fibrinolytic balance, including hs-CRP, IL-6, HOMA-IR, leptin, adiponectin, gamma-glutamyl transferase, E-selectin, and plasminogen activator inhibitor-1 antigen.
Not all pathways moved in parallel: fibrinogen, tissue plasminogen activator antigen, and thrombomodulin did not show consistent changes, underscoring that biomarker remodeling with tirzepatide is selective rather than uniform.
Because this was a post hoc biomarker analysis rather than an outcomes trial, the findings are hypothesis-generating with respect to cardiovascular event reduction, but they strengthen biologic plausibility for cardiometabolic benefit in obesity.
Clinical background
Obesity is a chronic, multisystem disease that promotes cardiovascular risk through more than excess body weight alone. Adipose tissue inflammation, insulin resistance, hepatic steatosis, endothelial dysfunction, and impaired fibrinolysis collectively contribute to atherosclerotic disease, heart failure risk, and metabolic deterioration. In routine care, clinicians typically follow body weight, blood pressure, glycemia, and lipids. Yet these traditional measures capture only part of the biological burden associated with obesity.
Tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, has already demonstrated substantial efficacy for weight loss and glycemic improvement. What has been less clear is how deeply it modifies upstream cardiovascular biology in people with obesity who do not necessarily have diabetes. That question matters, because cardiometabolic therapies increasingly are judged not only by changes on the scale, but by whether they favorably alter inflammatory, endothelial, thrombotic, and hepatic pathways that mediate long-term vascular risk.
The present post hoc analysis from SURMOUNT-1 addresses that gap by examining a broad panel of biomarkers over 72 weeks. The value of this analysis lies in its scope: rather than focusing on one or two markers, it evaluates multiple interconnected pathways that together provide a more integrated picture of cardiometabolic risk remodeling.
Study design and methods
SURMOUNT-1 was a randomized clinical trial evaluating tirzepatide in adults with overweight or obesity. In this post hoc substudy, investigators analyzed plasma biomarkers from 100 randomly selected treatment completers from each group assigned to placebo or tirzepatide 5 mg, 10 mg, or 15 mg once weekly. After exclusion of samples with low volume, 392 participants were included.
Biomarkers were measured at baseline, 24 weeks, and 72 weeks. The panel was organized into clinically relevant domains:
Inflammation: high-sensitivity C-reactive protein, interleukin-6, fibrinogen, and leukocytes.
Metabolic, adiposity, and hepatic stress: homeostatic model assessment of insulin resistance, leptin, gamma-glutamyl transferase, fibroblast growth factor-21, adiponectin, and free fatty acids.
Endothelial dysfunction: soluble intercellular adhesion molecule-1 and E-selectin.
Hemostasis and thrombosis: plasminogen activator inhibitor-1 antigen, tissue plasminogen activator antigen, thrombomodulin, and platelets.
The statistical approach was appropriate for repeated longitudinal measures. Biomarkers were log-transformed, changes over time were modeled using mixed models for repeated measures, and results were back-transformed to geometric mean ratios. The primary time point of interest was week 72. Investigators also explored Pearson correlations between log biomarker changes and weight change across pooled tirzepatide doses.
Several design features deserve attention. Random selection from each treatment group improves internal balance within the substudy, and the placebo comparator preserves the randomized trial framework. At the same time, this remained a post hoc, non-outcomes analysis restricted to treatment completers rather than the entire trial population, which affects interpretation.
Key results
At 72 weeks, tirzepatide was associated with significantly greater improvement than placebo in a wide range of biomarkers. The overall pattern was directionally coherent with reduced cardiometabolic stress, and many effects were dose-responsive.
Inflammatory biomarkers
High-sensitivity C-reactive protein showed some of the most striking reductions, with placebo-adjusted geometric mean decreases of 36.9%, 46.9%, and 54.6% for tirzepatide 5 mg, 10 mg, and 15 mg, respectively. Interleukin-6 also fell significantly, by 25.4%, 27.8%, and 30.2% across the three doses.
Leukocyte counts declined significantly with the 10-mg and 15-mg doses, by 8.6% and 10.0%, respectively, but not significantly with 5 mg. In contrast, fibrinogen did not show a consistent treatment-associated change. This distinction is important: tirzepatide appears to suppress selected inflammatory pathways robustly, but not every inflammatory biomarker tracked in parallel.
From a clinical perspective, the hs-CRP reductions are especially notable. hs-CRP integrates adipose-driven inflammation, hepatic acute-phase signaling, and systemic vascular risk. The magnitude of reduction observed here is larger than what many clinicians would expect from weight loss alone, although the study was not designed to formally disentangle direct drug effects from weight-mediated effects.
Metabolic, adiposity, and hepatic stress biomarkers
Insulin resistance improved substantially. HOMA-IR was reduced by 26.4%, 35.5%, and 39.1% with tirzepatide 5 mg, 10 mg, and 15 mg, respectively, compared with placebo. Leptin, a marker closely linked to adiposity and energy balance, fell by 44.4%, 59.3%, and 61.4%, among the largest relative changes in the entire panel.
Adiponectin increased by 21.1%, 35.1%, and 47.7%, suggesting a shift toward a more favorable adipose tissue secretory profile. Gamma-glutamyl transferase declined by 18.6%, 21.6%, and 32.7%, while fibroblast growth factor-21 declined by 27.4%, 27.6%, and 39.9%. Free fatty acids were significantly reduced only at the 15-mg dose, by 17.1%.
These findings deserve emphasis because they point beyond weight reduction toward broader metabolic normalization. Lower HOMA-IR indicates improved insulin sensitivity; lower leptin likely reflects reduced fat mass and altered adipocyte biology; rising adiponectin is generally associated with improved insulin sensitivity and anti-inflammatory effects; and reduced gamma-glutamyl transferase suggests less hepatic stress, potentially consistent with improved steatotic liver biology.
The fibroblast growth factor-21 result is intriguing. FGF-21 is often elevated in obesity and metabolic dysfunction, possibly reflecting compensatory stress signaling or relative resistance to endogenous FGF-21 action. Its reduction during tirzepatide therapy may therefore indicate reduced metabolic strain rather than loss of a beneficial hormone signal. That interpretation remains biologically plausible but not definitive.
Endothelial dysfunction
Endothelial biomarkers also improved, though with some dose dependence. Soluble intercellular adhesion molecule-1 was reduced significantly with 10 mg and 15 mg, by 9.7% and 11.1%, respectively, but not significantly with 5 mg. E-selectin declined significantly across all three doses, by 12.6%, 20.0%, and 26.4%.
These markers matter because endothelial activation is central to early atherogenesis and vascular inflammation. A reduction in adhesion molecules suggests a less pro-inflammatory, less adhesive endothelial state, potentially lowering leukocyte recruitment into the vascular wall. While biomarker shifts cannot substitute for imaging or outcomes data, they align with a vasculoprotective biological signal.
Hemostasis and thrombosis
Among hemostatic markers, plasminogen activator inhibitor-1 antigen improved consistently and substantially, decreasing by 41.4%, 35.6%, and 44.3% with 5 mg, 10 mg, and 15 mg, respectively. Platelets fell modestly and significantly only with 15 mg, by 6.0%. Tissue plasminogen activator antigen and thrombomodulin showed no consistent changes.
The PAI-1 finding is clinically relevant. Elevated PAI-1 is a hallmark of obesity-related hypofibrinolysis and is linked to visceral adiposity, insulin resistance, and prothrombotic risk. Large reductions in PAI-1 support the idea that tirzepatide favorably remodels fibrinolytic balance, although the study was not designed to assess thrombotic outcomes.
Overall pattern of effect
A practical way to understand this analysis is to separate biomarkers into three groups. First, there were robust responders: hs-CRP, IL-6, HOMA-IR, leptin, adiponectin, gamma-glutamyl transferase, E-selectin, and PAI-1. Second, there were partial or dose-dependent responders: leukocytes, free fatty acids, soluble intercellular adhesion molecule-1, and platelets. Third, there were non-consistent markers: fibrinogen, tissue plasminogen activator antigen, and thrombomodulin.
That pattern argues against nonspecific assay drift and in favor of biologically selective effects. Tirzepatide did not lower everything indiscriminately; instead, it appeared to meaningfully affect pathways tightly linked to adiposity, insulin resistance, low-grade inflammation, endothelial activation, and impaired fibrinolysis.
Mechanistic and clinical interpretation
Several mechanisms likely contribute to these biomarker changes. The most obvious is weight loss itself, which reduces adipose tissue inflammation, ectopic fat burden, and insulin resistance. However, the breadth of the changes raises the possibility that tirzepatide exerts additional biology through improved postprandial metabolism, reduced glucotoxicity, altered adipokine signaling, and favorable effects on hepatic and vascular function.
The combined GIP and GLP-1 receptor agonist mechanism may be relevant here. GLP-1 receptor agonists have established metabolic and cardiovascular effects, and outcome trials in diabetes have shown reductions in major adverse cardiovascular events for several drugs in that class. Tirzepatide shares some of that biology but also engages GIP signaling, which may influence adipocyte metabolism and energy handling. Whether the observed biomarker profile is quantitatively or qualitatively different from that seen with GLP-1 receptor agonism alone is an important but unanswered comparative question.
For clinicians, the central message is that tirzepatide appears to shift multiple upstream determinants of cardiovascular risk in a favorable direction over a relatively long time horizon. This is not equivalent to proving fewer myocardial infarctions, strokes, venous thromboembolic events, or heart failure hospitalizations in people with obesity, but it does strengthen mechanistic confidence that substantial weight loss with tirzepatide is accompanied by meaningful biological risk attenuation.
Strengths and limitations
This analysis has several strengths. It leverages a randomized, placebo-controlled trial framework; assesses multiple mechanistic domains simultaneously; includes follow-up to 72 weeks rather than only short-term measurements; and reports dose-stratified effects. The use of repeated-measures modeling and back-transformed geometric mean changes is methodologically sound for skewed biomarker data.
Limitations are equally important. First, the analysis was post hoc and included randomly selected treatment completers, not the full intention-to-treat population. This may enrich for participants who tolerated and responded to treatment, potentially affecting external validity. Second, the biomarker panel, while comprehensive, remains surrogate-based. Changes in circulating proteins and cell counts do not necessarily translate into hard clinical event reduction. Third, the abstract does not provide the detailed correlation coefficients between weight loss and biomarker change, so the extent to which effects were weight-mediated cannot be fully judged from the summary data alone. Fourth, the sample size for each arm was modest for biomarker work, particularly when examining markers with greater biological variability. Finally, the generalizability to people with established cardiovascular disease, advanced chronic kidney disease, or severe inflammatory states is uncertain.
Implications for practice and research
For current clinical practice, this study does not change prescribing on its own, but it adds depth to the rationale for tirzepatide use in obesity management. Many clinicians already recognize that substantial weight loss improves blood pressure, glycemia, sleep apnea burden, and quality of life. These data suggest that the benefit may extend more comprehensively into inflammatory, endothelial, hepatic, and fibrinolytic biology.
Several research directions follow. First, formal mediation analyses are needed to determine how much of the biomarker benefit is explained by weight loss versus direct pharmacologic effects. Second, comparisons with selective GLP-1 receptor agonists could clarify whether tirzepatide produces a distinct biomarker signature. Third, linking biomarker trajectories to imaging endpoints such as coronary plaque characteristics, epicardial fat, liver fat content, or vascular inflammation would improve translational relevance. Most importantly, cardiovascular outcomes data in obesity populations without diabetes will be needed to establish whether these biomarker improvements predict event reduction.
In a broader sense, this study reflects an evolving approach to obesity therapeutics. The field is moving from viewing obesity treatment as cosmetic or weight-centric toward understanding it as chronic disease modification across interconnected organ systems. Biomarker analyses cannot replace outcomes trials, but they often help explain why certain therapies may alter long-term risk.
Conclusion
This post hoc SURMOUNT-1 analysis shows that tirzepatide was associated with broad and durable improvements in cardiovascular risk biomarkers over 72 weeks in adults with overweight or obesity. The most consistent benefits were observed in inflammation, insulin resistance, adiposity-related signaling, hepatic stress, endothelial dysfunction, and impaired fibrinolysis, with many effects showing dose response.
The findings are biologically compelling and clinically relevant, particularly the marked reductions in hs-CRP, IL-6, HOMA-IR, leptin, E-selectin, and PAI-1, alongside increased adiponectin. At the same time, the absence of consistent changes in some biomarkers and the post hoc nature of the analysis argue for caution. These results should be interpreted as mechanistic support for cardiometabolic benefit rather than definitive proof of cardiovascular event reduction. Even so, they meaningfully expand our understanding of how tirzepatide may remodel cardiovascular risk in obesity.
Funding, registration, and citation
Trial registration: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight, ClinicalTrials.gov identifier NCT04184622.
Funding: SURMOUNT-1 was sponsored by Eli Lilly and Company.
Primary citation: Sattar N, Linetzky B, Ruotolo G, Verma S, Sourij H, Wang H, Vanderman K, Wilson JM, Griffin RM, Stefanski A, Ridker PM. Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis. Journal of the American College of Cardiology. 2026-06-03. PMID: 42233927.
References
1. Sattar N, Linetzky B, Ruotolo G, Verma S, Sourij H, Wang H, Vanderman K, Wilson JM, Griffin RM, Stefanski A, Ridker PM. Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis. Journal of the American College of Cardiology. 2026-06-03. PMID: 42233927.
2. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-216. doi:10.1056/NEJMoa2206038.
3. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002. doi:10.1056/NEJMoa2032183.
4. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Jodar E, Kendall DM, Khurmi NS, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221-2232. doi:10.1056/NEJMoa2307563.
5. Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P, St-Onge MP; American Heart Association. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143:e984-e1010. doi:10.1161/CIR.0000000000000973.
